Company Encyclopedia
View More
name
Fibrogen
FGEN.US
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc.
1.946 T
FGEN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking151/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE40.09%A
    • Profit Margin2598.87%A
    • Gross Margin-6.97%E
  • Growth ScoreA
    • Revenue YoY117.53%A
    • Net Profit YoY277.07%A
    • Total Assets YoY-48.18%E
    • Net Assets YoY108.67%A
  • Cash ScoreB
    • Cash Flow Margin3.85%C
    • OCF YoY117.53%A
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreE
    • Gearing Ratio87.24%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties

    William Blair analyst Andy Hsieh has maintained a Hold rating on FibroGen (FGEN) stock due to uncertainties surrounding the company's financial status and strategic developments. Following the sale of FibroGen China to AstraZeneca, the company has cash reserves of $121.1 million, expected to last until 2028, although costs for a Phase III study may shorten this to 2027. Ongoing trials and their outcomes remain uncertain, contributing to the cautious outlook. Another report also reiterated a Hold rating with an $11.00 price target.

    Tip Ranks·
    US
    FGEN
    +1.60%
    Tip Ranks·
    US
    FGEN
    +1.60%

    FibroGen’s Strategic Moves and Financial Highlights

    FibroGen (FGEN) reported its Q3 earnings, highlighting strategic and financial developments. The company sold its China operations to AstraZeneca for $220 million, simplifying its capital structure and extending its cash runway to 2028. Q3 revenue reached $1.1 million, up from $0.1 million last year, while net loss decreased to $13.1 million from $48.3 million. FibroGen initiated a Phase 2 trial for FG-3246 and reached an agreement with the FDA for a Phase 3 trial for roxadustat, with plans to submit the protocol in Q4 2025 and present results in early 2026.

    Tip Ranks·
    US
    FGEN
    +1.60%
    Tip Ranks·
    US
    FGEN
    +1.60%

    Fibrogen | 10-Q: FY2025 Q3 Revenue: USD 1.076 M

    LB filings·
    US
    FGEN
    +1.60%
    LB filings·
    US
    FGEN
    +1.60%

    FibroGen posts Q3 net income of $200.6 mln after sale of China operations

    FibroGen reported a Q3 net income of $200.6 million, primarily due to the sale of its China operations to AstraZeneca for $220 million. Revenue from continuing operations rose to $1.1 million. The company anticipates its cash resources will support operations until 2028, with interim results from the FG-3246 trial expected in 2026. Analysts maintain a "buy" rating on FibroGen, with a median 12-month price target of $43.00, significantly above its recent closing price of $11.03.

    Reuters·
    US
    FGEN
    +1.60%
    Reuters·
    US
    FGEN
    +1.60%

    Fibrogen | 8-K: FY2025 Q3 Revenue: USD 1.076 M

    LB filings·
    US
    FGEN
    +1.60%
    LB filings·
    US
    FGEN
    +1.60%
    © 2025 Longbridge｜Disclaimer